The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sunitinib dosing, toxicity, and outcomes in first-line advanced renal cell carcinoma (aRCC): A U.S. Oncology Network (USON) retrospective study.
Ian D. Schnadig
No relevant relationships to disclose
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Hsingwen Chung
No relevant relationships to disclose
Rahul Dhanda
No relevant relationships to disclose
Melissa Halm
No relevant relationships to disclose
Michael T. Forsyth
No relevant relationships to disclose
Nicholas J. Vogelzang
Consultant or Advisory Role - Algeta/Bayer; Amgen; Boehringer Ingelheim; Celgene; Clinical Care Options; Dendreon; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson/Centocor; Lilly; Novartis; Pfizer; Sanofi ; Takeda/Millennium; US Oncology; Veridex; Viamet Pharmaceuticals; Wilex
Honoraria - Clinical Care Options; Dendreon; Genentech; Johnson & Johnson/Centocor; Lilly; Novartis; Pfizer; Sanofi ; US Oncology; Veridex; Wilex
Research Funding - Algeta/Bayer; GlaxoSmithKline; Johnson & Johnson/Centocor; Novartis; Pfizer; Takeda/Millennium; Tokai; US Oncology; Veridex; Wilex